CIAM
NMRA icon

Caitong International Asset Management’s Neumora Therapeutics NMRA Stock Holding History

Caitong International Asset Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41 Buy
21
+16
+320% +$41 ﹤0.01% 2030
2025
Q4 		$9 Buy
+5
New +$11 ﹤0.01% 1811
2025
Q3 		– Sell
-1
Closed -$1 – 2329
2025
Q2 		$1 Sell
1
-2,649
-100% -$2.01K ﹤0.01% 1929
2025
Q1 		$2.65K Buy
2,650
+2,551
+2,577% +$4.37K ﹤0.01% 1239
2024
Q4 		$1.05K Buy
+99
New +$1.19K ﹤0.01% 1320

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Caitong International Asset Management's NMRA Position: Q1 2026 in Review

Caitong International Asset Management increased its Neumora Therapeutics (NMRA) stake by 320% in Q1 2026, buying an estimated $41 and bringing the position to 21 shares worth $41. The position accounts for ﹤0.01% of the portfolio, ranked #2030.

Caitong International Asset Management first reported a position in NMRA in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.65K in Q1 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Caitong International Asset Management held 21 shares of Neumora Therapeutics worth $41 as of Q1 2026.
  • Caitong International Asset Management bought 16 Neumora Therapeutics shares in Q1 2026, an estimated $41.
  • Neumora Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2030 holding.
  • Caitong International Asset Management first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Caitong International Asset Management's Neumora Therapeutics position peaked at $2.65K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.